iShares MSCI Canada (TSX) vs NeoGenomics Inc. Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.17B), while NeoGenomics Inc. Common Stock trades at $16.83 (market cap $2.14B). The key difference: iShares MSCI Canada (TSX) is far larger — about 3.4× NeoGenomics Inc. Common Stock's market cap, and iShares MSCI Canada (TSX) is more actively traded (3,409,217 versus 2,228,400). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| EWC | NEO | |
|---|---|---|
Market Cap | $7.17B | $2.14B |
Volume | 3,409,217 | 2,228,400 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $19.91 |
52-Week Low | $49.72 | $7.19 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.44B |
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.91, up 0.77% today, with a bullish technical signal from moving averages but neutral oscillators. The stock faces support at $59 and resistance at $60. Recent news highlights Canada's trade tensions with the U.S. and potential EU associate membership, impacting market sentiment.
Outlook is clouded by trade policy uncertainty, though diversification efforts with India and Europe offer growth avenues. Key risks include U.S. tariff escalations and economic volatility. Analyst sentiment is mixed, balancing geopolitical headwinds against strategic partnerships.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →